Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  7/31/2012
Teva Investigational Site 093
mi
from
Marina Del Rey, CA
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 7/31/2012
Teva Investigational Site 093
mi
from
Marina Del Rey, CA
Click here to add this to my saved trials
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  7/31/2012
Teva Investigational Site
mi
from
San Diego, CA
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 7/31/2012
Teva Investigational Site
mi
from
San Diego, CA
Click here to add this to my saved trials
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  7/31/2012
Teva Investigational Site
mi
from
Fort Collins, CO
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 7/31/2012
Teva Investigational Site
mi
from
Fort Collins, CO
Click here to add this to my saved trials
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  7/31/2012
Teva Investigational Site 106
mi
from
Fort Myers, FL
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 7/31/2012
Teva Investigational Site 106
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  7/31/2012
Teva Investigational Site 094
mi
from
Port St Lucie, FL
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 7/31/2012
Teva Investigational Site 094
mi
from
Port St Lucie, FL
Click here to add this to my saved trials
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  7/31/2012
Teva Investigational Site 096
mi
from
Atlanta, GA
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 7/31/2012
Teva Investigational Site 096
mi
from
Atlanta, GA
Click here to add this to my saved trials
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  7/31/2012
Teva Investigational Site 103
mi
from
Baton Rouge, LA
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 7/31/2012
Teva Investigational Site 103
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  7/31/2012
Teva Investigational Site 098
mi
from
Ann Arbor, MI
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 7/31/2012
Teva Investigational Site 098
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  7/31/2012
Teva Investigational Site 11
mi
from
Detroit, MI
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 7/31/2012
Teva Investigational Site 11
mi
from
Detroit, MI
Click here to add this to my saved trials
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  7/31/2012
Teva Investigational Site 1021
mi
from
Rochester, MN
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 7/31/2012
Teva Investigational Site 1021
mi
from
Rochester, MN
Click here to add this to my saved trials
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  7/31/2012
Teva Investigational Site 60
mi
from
Las Vegas, NV
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 7/31/2012
Teva Investigational Site 60
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  7/31/2012
Teva Investigational Site
mi
from
Cincinnati, OH
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 7/31/2012
Teva Investigational Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  7/31/2012
Teva Investigational Site 266
mi
from
Greensboro, SC
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 7/31/2012
Teva Investigational Site 266
mi
from
Greensboro, SC
Click here to add this to my saved trials
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  7/31/2012
Teva Investigational Site 102
mi
from
Myrtle Beach, SC
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 7/31/2012
Teva Investigational Site 102
mi
from
Myrtle Beach, SC
Click here to add this to my saved trials
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  7/31/2012
Teva Investigational Site 084
mi
from
Memphis, TN
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 7/31/2012
Teva Investigational Site 084
mi
from
Memphis, TN
Click here to add this to my saved trials
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  7/31/2012
Teva Investigational Site 1310
mi
from
Nashville, TN
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 7/31/2012
Teva Investigational Site 1310
mi
from
Nashville, TN
Click here to add this to my saved trials
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  7/31/2012
Teva Investigational Site
mi
from
San Antonio, TX
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 7/31/2012
Teva Investigational Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  7/31/2012
Teva Investigational Site 059
mi
from
Tyler, TX
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 7/31/2012
Teva Investigational Site 059
mi
from
Tyler, TX
Click here to add this to my saved trials
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  7/31/2012
Teva Investigational Site 047
mi
from
Newport, VA
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 7/31/2012
Teva Investigational Site 047
mi
from
Newport, VA
Click here to add this to my saved trials
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  7/31/2012
Teva Investigational Site 104
mi
from
Norfolk, VA
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 7/31/2012
Teva Investigational Site 104
mi
from
Norfolk, VA
Click here to add this to my saved trials
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  7/31/2012
Teva Investigational Site
mi
from
Seattle, WA
Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer
A Randomized Phase 3 Study Comparing Standard First-Line Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With Custirsen (OGX-011) in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 7/31/2012
Teva Investigational Site
mi
from
Seattle, WA
Click here to add this to my saved trials
A Clinical Study in Cancer Patients to Investigate the Potential Impact of Custirsen, on the Blood Levels of the Chemotherapeutic Drug, Paclitaxel, When Given Together as Part of a Treatment Regimen
An Open-Label, One-Arm, One-Sequence Crossover Drug-Drug Interaction Study in Advanced Solid Tumor Subjects Subjects to Evaluate the Potential Effect of Custirsen (OGX-011) on the Pharmacokinetics of Paclitaxel
Status: Enrolling
Updated:  7/31/2012
Teva Investigational Site 11
mi
from
Detroit, MI
A Clinical Study in Cancer Patients to Investigate the Potential Impact of Custirsen, on the Blood Levels of the Chemotherapeutic Drug, Paclitaxel, When Given Together as Part of a Treatment Regimen
An Open-Label, One-Arm, One-Sequence Crossover Drug-Drug Interaction Study in Advanced Solid Tumor Subjects Subjects to Evaluate the Potential Effect of Custirsen (OGX-011) on the Pharmacokinetics of Paclitaxel
Status: Enrolling
Updated: 7/31/2012
Teva Investigational Site 11
mi
from
Detroit, MI
Click here to add this to my saved trials
A Clinical Study in Cancer Patients to Investigate the Potential Impact of Custirsen, on the Blood Levels of the Chemotherapeutic Drug, Paclitaxel, When Given Together as Part of a Treatment Regimen
An Open-Label, One-Arm, One-Sequence Crossover Drug-Drug Interaction Study in Advanced Solid Tumor Subjects Subjects to Evaluate the Potential Effect of Custirsen (OGX-011) on the Pharmacokinetics of Paclitaxel
Status: Enrolling
Updated:  7/31/2012
Teva Investigational Site
mi
from
Dallas, TX
A Clinical Study in Cancer Patients to Investigate the Potential Impact of Custirsen, on the Blood Levels of the Chemotherapeutic Drug, Paclitaxel, When Given Together as Part of a Treatment Regimen
An Open-Label, One-Arm, One-Sequence Crossover Drug-Drug Interaction Study in Advanced Solid Tumor Subjects Subjects to Evaluate the Potential Effect of Custirsen (OGX-011) on the Pharmacokinetics of Paclitaxel
Status: Enrolling
Updated: 7/31/2012
Teva Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
A Clinical Study in Cancer Patients to Investigate the Potential Impact of Custirsen, on the Blood Levels of the Chemotherapeutic Drug, Paclitaxel, When Given Together as Part of a Treatment Regimen
An Open-Label, One-Arm, One-Sequence Crossover Drug-Drug Interaction Study in Advanced Solid Tumor Subjects Subjects to Evaluate the Potential Effect of Custirsen (OGX-011) on the Pharmacokinetics of Paclitaxel
Status: Enrolling
Updated:  7/31/2012
Teva Investigational Site
mi
from
San Antonio, TX
A Clinical Study in Cancer Patients to Investigate the Potential Impact of Custirsen, on the Blood Levels of the Chemotherapeutic Drug, Paclitaxel, When Given Together as Part of a Treatment Regimen
An Open-Label, One-Arm, One-Sequence Crossover Drug-Drug Interaction Study in Advanced Solid Tumor Subjects Subjects to Evaluate the Potential Effect of Custirsen (OGX-011) on the Pharmacokinetics of Paclitaxel
Status: Enrolling
Updated: 7/31/2012
Teva Investigational Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Clinical Study in Cancer Patients to Investigate the Potential Impact of Custirsen, on the Blood Levels of the Chemotherapeutic Drug, Paclitaxel, When Given Together as Part of a Treatment Regimen
An Open-Label, One-Arm, One-Sequence Crossover Drug-Drug Interaction Study in Advanced Solid Tumor Subjects Subjects to Evaluate the Potential Effect of Custirsen (OGX-011) on the Pharmacokinetics of Paclitaxel
Status: Enrolling
Updated:  7/31/2012
Teva Investigational Site 10530
mi
from
Tacoma, WA
A Clinical Study in Cancer Patients to Investigate the Potential Impact of Custirsen, on the Blood Levels of the Chemotherapeutic Drug, Paclitaxel, When Given Together as Part of a Treatment Regimen
An Open-Label, One-Arm, One-Sequence Crossover Drug-Drug Interaction Study in Advanced Solid Tumor Subjects Subjects to Evaluate the Potential Effect of Custirsen (OGX-011) on the Pharmacokinetics of Paclitaxel
Status: Enrolling
Updated: 7/31/2012
Teva Investigational Site 10530
mi
from
Tacoma, WA
Click here to add this to my saved trials
Study to Assess Safety, Tolerability and PK of AZD1480 in Patients With Solid Tumours
A Phase I, Open-Label, Multi-Center, Dose-Escalation Study to Assess the Safety and Tolerability, and Pharmacokinetics of AZD1480 Administered as Daily Oral Monotherapy in Patients With Advanced Solid Malignancies in the Escalation Phase and EGFR or ROS Mutant NSCLC or Non-Smokers With Lung Metastasis in the Expansion Phase.
Status: Enrolling
Updated:  8/2/2012
Clinical Research Facility
mi
from
Denver, CO
Study to Assess Safety, Tolerability and PK of AZD1480 in Patients With Solid Tumours
A Phase I, Open-Label, Multi-Center, Dose-Escalation Study to Assess the Safety and Tolerability, and Pharmacokinetics of AZD1480 Administered as Daily Oral Monotherapy in Patients With Advanced Solid Malignancies in the Escalation Phase and EGFR or ROS Mutant NSCLC or Non-Smokers With Lung Metastasis in the Expansion Phase.
Status: Enrolling
Updated: 8/2/2012
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
Study to Assess Safety, Tolerability and PK of AZD1480 in Patients With Solid Tumours
A Phase I, Open-Label, Multi-Center, Dose-Escalation Study to Assess the Safety and Tolerability, and Pharmacokinetics of AZD1480 Administered as Daily Oral Monotherapy in Patients With Advanced Solid Malignancies in the Escalation Phase and EGFR or ROS Mutant NSCLC or Non-Smokers With Lung Metastasis in the Expansion Phase.
Status: Enrolling
Updated:  8/2/2012
Clinical Research Facility
mi
from
Detroit, MI
Study to Assess Safety, Tolerability and PK of AZD1480 in Patients With Solid Tumours
A Phase I, Open-Label, Multi-Center, Dose-Escalation Study to Assess the Safety and Tolerability, and Pharmacokinetics of AZD1480 Administered as Daily Oral Monotherapy in Patients With Advanced Solid Malignancies in the Escalation Phase and EGFR or ROS Mutant NSCLC or Non-Smokers With Lung Metastasis in the Expansion Phase.
Status: Enrolling
Updated: 8/2/2012
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
Study to Assess Safety, Tolerability and PK of AZD1480 in Patients With Solid Tumours
A Phase I, Open-Label, Multi-Center, Dose-Escalation Study to Assess the Safety and Tolerability, and Pharmacokinetics of AZD1480 Administered as Daily Oral Monotherapy in Patients With Advanced Solid Malignancies in the Escalation Phase and EGFR or ROS Mutant NSCLC or Non-Smokers With Lung Metastasis in the Expansion Phase.
Status: Enrolling
Updated:  8/2/2012
Clinical Research Facility
mi
from
Allentown, PA
Study to Assess Safety, Tolerability and PK of AZD1480 in Patients With Solid Tumours
A Phase I, Open-Label, Multi-Center, Dose-Escalation Study to Assess the Safety and Tolerability, and Pharmacokinetics of AZD1480 Administered as Daily Oral Monotherapy in Patients With Advanced Solid Malignancies in the Escalation Phase and EGFR or ROS Mutant NSCLC or Non-Smokers With Lung Metastasis in the Expansion Phase.
Status: Enrolling
Updated: 8/2/2012
Clinical Research Facility
mi
from
Allentown, PA
Click here to add this to my saved trials
Sildenafil Trial in Children and Young Adults With CF
Randomized Controlled Study of Sildenafil in Children and Young Adults With Mild to Moderate Cystic Fibrosis Lung Disease
Status: Enrolling
Updated:  8/2/2012
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Sildenafil Trial in Children and Young Adults With CF
Randomized Controlled Study of Sildenafil in Children and Young Adults With Mild to Moderate Cystic Fibrosis Lung Disease
Status: Enrolling
Updated: 8/2/2012
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Study of Combined Fulvestrant and RAD001 in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure
A Phase II Study of Combined Fulvestrant (Faslodex) and RAD001 (Everolimus) in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure
Status: Enrolling
Updated:  8/6/2012
University of Kentucky
mi
from
Lexington, KY
Study of Combined Fulvestrant and RAD001 in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure
A Phase II Study of Combined Fulvestrant (Faslodex) and RAD001 (Everolimus) in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure
Status: Enrolling
Updated: 8/6/2012
University of Kentucky
mi
from
Lexington, KY
Click here to add this to my saved trials
A Study to Evaluate the Effectiveness of 5-Azacitidine and Bevacizumab in Advanced Renal Cell Carcinoma
A Phase I/II Study Evaluating The Efficacy OF 5-Azacitidine And Bevacizumab In Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  8/6/2012
University of Kansas Medical Center
mi
from
Kansas City, KA
A Study to Evaluate the Effectiveness of 5-Azacitidine and Bevacizumab in Advanced Renal Cell Carcinoma
A Phase I/II Study Evaluating The Efficacy OF 5-Azacitidine And Bevacizumab In Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 8/6/2012
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
A Study to Evaluate the Effectiveness of 5-Azacitidine and Bevacizumab in Advanced Renal Cell Carcinoma
A Phase I/II Study Evaluating The Efficacy OF 5-Azacitidine And Bevacizumab In Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  8/6/2012
Stormont-Vail Cotton O'Neil Cancer Center
mi
from
Topeka, KA
A Study to Evaluate the Effectiveness of 5-Azacitidine and Bevacizumab in Advanced Renal Cell Carcinoma
A Phase I/II Study Evaluating The Efficacy OF 5-Azacitidine And Bevacizumab In Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 8/6/2012
Stormont-Vail Cotton O'Neil Cancer Center
mi
from
Topeka, KA
Click here to add this to my saved trials
Reduced-intensity Therapy for Advanced Oropharyngeal Cancer in Non-smoking Human Papilloma Virus (HPV)-16 Positive Patients
Reduced-intensity Therapy for Advanced Oropharyngeal Cancer in Non-smoking Human Papilloma Virus (HPV)-16 Positive Patients
Status: Enrolling
Updated:  8/7/2012
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Reduced-intensity Therapy for Advanced Oropharyngeal Cancer in Non-smoking Human Papilloma Virus (HPV)-16 Positive Patients
Reduced-intensity Therapy for Advanced Oropharyngeal Cancer in Non-smoking Human Papilloma Virus (HPV)-16 Positive Patients
Status: Enrolling
Updated: 8/7/2012
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer
Phase II Study of Single Agent Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer With No Prior PARP Exposure or Prior PARP Inhibitor Exposure
Status: Enrolling
Updated:  8/7/2012
Dana-Farber Cancer Institute
mi
from
Boston, MA
Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer
Phase II Study of Single Agent Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer With No Prior PARP Exposure or Prior PARP Inhibitor Exposure
Status: Enrolling
Updated: 8/7/2012
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of IMC-3G3 in Soft Tissue Sarcoma
A Phase 1b/2 Randomized Phase 2 Study Evaluating the Efficacy of Doxorubicin With or Without a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in the Treatment of Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated:  8/9/2012
ImClone Investigational Site
mi
from
Scottsdale, AZ
A Study of IMC-3G3 in Soft Tissue Sarcoma
A Phase 1b/2 Randomized Phase 2 Study Evaluating the Efficacy of Doxorubicin With or Without a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in the Treatment of Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated: 8/9/2012
ImClone Investigational Site
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Study of IMC-3G3 in Soft Tissue Sarcoma
A Phase 1b/2 Randomized Phase 2 Study Evaluating the Efficacy of Doxorubicin With or Without a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in the Treatment of Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated:  8/9/2012
ImClone Investigational Site
mi
from
Alhambra, CA
A Study of IMC-3G3 in Soft Tissue Sarcoma
A Phase 1b/2 Randomized Phase 2 Study Evaluating the Efficacy of Doxorubicin With or Without a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in the Treatment of Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated: 8/9/2012
ImClone Investigational Site
mi
from
Alhambra, CA
Click here to add this to my saved trials
A Study of IMC-3G3 in Soft Tissue Sarcoma
A Phase 1b/2 Randomized Phase 2 Study Evaluating the Efficacy of Doxorubicin With or Without a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in the Treatment of Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated:  8/9/2012
ImClone Investigational Site
mi
from
Aurora, CO
A Study of IMC-3G3 in Soft Tissue Sarcoma
A Phase 1b/2 Randomized Phase 2 Study Evaluating the Efficacy of Doxorubicin With or Without a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in the Treatment of Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated: 8/9/2012
ImClone Investigational Site
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study of IMC-3G3 in Soft Tissue Sarcoma
A Phase 1b/2 Randomized Phase 2 Study Evaluating the Efficacy of Doxorubicin With or Without a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in the Treatment of Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated:  8/9/2012
ImClone Investigational Site
mi
from
Fort Lauderdale, FL
A Study of IMC-3G3 in Soft Tissue Sarcoma
A Phase 1b/2 Randomized Phase 2 Study Evaluating the Efficacy of Doxorubicin With or Without a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in the Treatment of Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated: 8/9/2012
ImClone Investigational Site
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
A Study of IMC-3G3 in Soft Tissue Sarcoma
A Phase 1b/2 Randomized Phase 2 Study Evaluating the Efficacy of Doxorubicin With or Without a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in the Treatment of Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated:  8/9/2012
ImClone Investigational Site
mi
from
Atlanta, GA
A Study of IMC-3G3 in Soft Tissue Sarcoma
A Phase 1b/2 Randomized Phase 2 Study Evaluating the Efficacy of Doxorubicin With or Without a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in the Treatment of Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated: 8/9/2012
ImClone Investigational Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study of IMC-3G3 in Soft Tissue Sarcoma
A Phase 1b/2 Randomized Phase 2 Study Evaluating the Efficacy of Doxorubicin With or Without a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in the Treatment of Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated:  8/9/2012
ImClone Investigational Site
mi
from
Alton, IL
A Study of IMC-3G3 in Soft Tissue Sarcoma
A Phase 1b/2 Randomized Phase 2 Study Evaluating the Efficacy of Doxorubicin With or Without a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in the Treatment of Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated: 8/9/2012
ImClone Investigational Site
mi
from
Alton, IL
Click here to add this to my saved trials
A Study of IMC-3G3 in Soft Tissue Sarcoma
A Phase 1b/2 Randomized Phase 2 Study Evaluating the Efficacy of Doxorubicin With or Without a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in the Treatment of Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated:  8/9/2012
ImClone Investigational Site
mi
from
Minneapolis, MN
A Study of IMC-3G3 in Soft Tissue Sarcoma
A Phase 1b/2 Randomized Phase 2 Study Evaluating the Efficacy of Doxorubicin With or Without a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in the Treatment of Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated: 8/9/2012
ImClone Investigational Site
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Study of IMC-3G3 in Soft Tissue Sarcoma
A Phase 1b/2 Randomized Phase 2 Study Evaluating the Efficacy of Doxorubicin With or Without a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in the Treatment of Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated:  8/9/2012
ImClone Investigational Site
mi
from
St. Louis, MO
A Study of IMC-3G3 in Soft Tissue Sarcoma
A Phase 1b/2 Randomized Phase 2 Study Evaluating the Efficacy of Doxorubicin With or Without a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in the Treatment of Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated: 8/9/2012
ImClone Investigational Site
mi
from
St. Louis, MO
Click here to add this to my saved trials
A Study of IMC-3G3 in Soft Tissue Sarcoma
A Phase 1b/2 Randomized Phase 2 Study Evaluating the Efficacy of Doxorubicin With or Without a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in the Treatment of Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated:  8/9/2012
ImClone Investigational Site
mi
from
New York, NY
A Study of IMC-3G3 in Soft Tissue Sarcoma
A Phase 1b/2 Randomized Phase 2 Study Evaluating the Efficacy of Doxorubicin With or Without a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in the Treatment of Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated: 8/9/2012
ImClone Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
A Study of IMC-3G3 in Soft Tissue Sarcoma
A Phase 1b/2 Randomized Phase 2 Study Evaluating the Efficacy of Doxorubicin With or Without a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in the Treatment of Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated:  8/9/2012
ImClone Investigational Site
mi
from
Charlotte, NC
A Study of IMC-3G3 in Soft Tissue Sarcoma
A Phase 1b/2 Randomized Phase 2 Study Evaluating the Efficacy of Doxorubicin With or Without a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in the Treatment of Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated: 8/9/2012
ImClone Investigational Site
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Study of IMC-3G3 in Soft Tissue Sarcoma
A Phase 1b/2 Randomized Phase 2 Study Evaluating the Efficacy of Doxorubicin With or Without a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in the Treatment of Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated:  8/9/2012
ImClone Investigational Site
mi
from
Cincinnati, OH
A Study of IMC-3G3 in Soft Tissue Sarcoma
A Phase 1b/2 Randomized Phase 2 Study Evaluating the Efficacy of Doxorubicin With or Without a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in the Treatment of Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated: 8/9/2012
ImClone Investigational Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study of IMC-3G3 in Soft Tissue Sarcoma
A Phase 1b/2 Randomized Phase 2 Study Evaluating the Efficacy of Doxorubicin With or Without a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in the Treatment of Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated:  8/9/2012
ImClone Investigational Site
mi
from
Charleston, SC
A Study of IMC-3G3 in Soft Tissue Sarcoma
A Phase 1b/2 Randomized Phase 2 Study Evaluating the Efficacy of Doxorubicin With or Without a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in the Treatment of Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated: 8/9/2012
ImClone Investigational Site
mi
from
Charleston, SC
Click here to add this to my saved trials
A Study of IMC-3G3 in Soft Tissue Sarcoma
A Phase 1b/2 Randomized Phase 2 Study Evaluating the Efficacy of Doxorubicin With or Without a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in the Treatment of Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated:  8/9/2012
ImClone Investigational Site
mi
from
Memphis, TN
A Study of IMC-3G3 in Soft Tissue Sarcoma
A Phase 1b/2 Randomized Phase 2 Study Evaluating the Efficacy of Doxorubicin With or Without a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in the Treatment of Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated: 8/9/2012
ImClone Investigational Site
mi
from
Memphis, TN
Click here to add this to my saved trials
A Study of IMC-3G3 in Soft Tissue Sarcoma
A Phase 1b/2 Randomized Phase 2 Study Evaluating the Efficacy of Doxorubicin With or Without a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in the Treatment of Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated:  8/9/2012
ImClone Investigational Site
mi
from
Dallas, TX
A Study of IMC-3G3 in Soft Tissue Sarcoma
A Phase 1b/2 Randomized Phase 2 Study Evaluating the Efficacy of Doxorubicin With or Without a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in the Treatment of Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated: 8/9/2012
ImClone Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of IMC-3G3 in Soft Tissue Sarcoma
A Phase 1b/2 Randomized Phase 2 Study Evaluating the Efficacy of Doxorubicin With or Without a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in the Treatment of Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated:  8/9/2012
ImClone Investigational Site
mi
from
Everett, WA
A Study of IMC-3G3 in Soft Tissue Sarcoma
A Phase 1b/2 Randomized Phase 2 Study Evaluating the Efficacy of Doxorubicin With or Without a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in the Treatment of Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated: 8/9/2012
ImClone Investigational Site
mi
from
Everett, WA
Click here to add this to my saved trials
A Study of IMC-3G3 in Soft Tissue Sarcoma
A Phase 1b/2 Randomized Phase 2 Study Evaluating the Efficacy of Doxorubicin With or Without a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in the Treatment of Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated:  8/9/2012
ImClone Investigational Site
mi
from
Madison, WI
A Study of IMC-3G3 in Soft Tissue Sarcoma
A Phase 1b/2 Randomized Phase 2 Study Evaluating the Efficacy of Doxorubicin With or Without a Human Anti-PDGFRα Monoclonal Antibody (IMC-3G3) in the Treatment of Advanced Soft Tissue Sarcoma
Status: Enrolling
Updated: 8/9/2012
ImClone Investigational Site
mi
from
Madison, WI
Click here to add this to my saved trials